Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618874 | 0.99 | PDE2A (0.38) | PDE2AKCNK3ALDH1A1MEN1MAPK1 | |
| SCHEMBL13618891 | 0.84 | NPC1 (0.35) | PDE2AALDH1A1MEN1KMT2ADGAT1 | |
| SCHEMBL13618881 | 0.82 | FFAR1 (0.34) | ALDH1A1MEN1KMT2ADGAT1 | |
| SCHEMBL13618873 | 0.81 | MEN1 (0.33) | ALDH1A1MEN1KMT2ADGAT1 | |
| SCHEMBL13618886 | 0.75 | HSD17B1 (0.50) | ALDH1A1MEN1MAPK1KMT2AHSD17B1 | |
| SCHEMBL13618885 | 0.75 | HSD17B1 (0.48) | KCNK3ALDH1A1MEN1MAPK1KMT2A | |
| SCHEMBL13618880 | 0.75 | HSD17B1 (0.43) | KCNK3ALDH1A1MEN1MAPK1KMT2A | |
| SCHEMBL13618872 | 0.74 | HSD17B1 (0.45) | ALDH1A1MEN1MAPK1KMT2AHSD17B1 | |
| SCHEMBL13618878 | 0.74 | HSD17B1 (0.52) | ALDH1A1MEN1MAPK1KMT2AHSD17B1 | |
| SCHEMBL13618876 | 0.74 | HSD17B1 (0.49) | ALDH1A1MEN1MAPK1KMT2AHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | PDE2A 2670/4885KCNK3 1742/4885ALDH1A1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.